CK Cell Technologies Pty Ltd

Site

CK Cell Technologies Pty Ltd

Accreditation No.

20531

Site No.

24597

Date of Accreditation

04 Aug 2021

Address

Unit 31, 11 - 13 Brookhollow Avenue
Baulkham Hills, NSW 2153
Australia

ckcelltechnologies.com

Contact

Dr Kuldip Sidhu P: +61 0401766055

Availability

Services available to external clients

CK Cell Technologies Pty Ltd address map

Scope of Accreditation

Print scopes

Withdrawn 30 Jun 2026

CK Cell Technologies Pty Ltd

ISO/IEC 17025 (2017)

Healthcare, Pharmaceutical and Media Products

Withdrawn
Service Product Determinant Technique
Analysis in support of research Conditioned media; Exosomes and other cell-free products derived from stem cells; Human embryonic stem cells (hESC); Induced pluripotent stem cells (iPSC); Mesenchymal stem cells (MSC); Reprogrammed induced pluripotent stem cells (iPSC) Characterisation of stem cell based diagnostic and therapeutic products; Differentiation of stem cells; Identification of cytokines; Identification of growth factor; Protein identification; Quantification of proteins; RNA gene expression Bicinchoninic acid (BCA) protein assay; Cytokine array; Exosome extraction; Flow cytometry; Polymerase chain reaction (PCR); Trilineage differentiation, staining and quantification
Human adipose tissue; Human dental tissue; Whole blood Impacts of stem cell based diagnostic and therapeutic products on neurodegenerative disorders, osteoarthritis, skin regeneration and repair, spinal cord injury, diabetic foot ulcer, wound healing and acute respiratory distress syndrome Isolation of peripheral blood mononuclear cells (PBMC); Isolation, propagation and cryopreservation of stem cells; Lyophilisation; Preparation of conditioned media; Reprogramming of peripheral blood mononuclear cells (PBMC) to Induced pluripotent stem cells (iPSC)

ISO/IEC 17025 (2017) interpreted for research (2)

Healthcare, Pharmaceutical and Media Products

Withdrawn
Service Product Determinant Technique Procedure
Conduct of research in support of regenerative medicine Human adipose tissue; Human dental tissue; Whole blood Impacts on neurodegenerative disorders, osteoarthritis, skin regeneration and repair, spinal cord injury, diabetic foot ulcer, wound healing and acute respiratory distress syndrome Differentiation of Induced pluripotent stem cells (iPSC) to mesenchymal stem cells (MSC) lineages; Isolation of peripheral blood mononuclear cells (PBMC); Isolation, propagation and cryopreservation of stem cells; Lyophilisation; Preparation of conditioned media; Reprogramming of peripheral blood mononuclear cells (PBMC) to Induced pluripotent stem cells (iPSC) in-house methods
Conduct of research in support of the development of stem cell based diagnostic and therapeutic products Conditioned media; Exosomes and other cell-free products derived from stem cells; Human embryonic stem cells (hESC); Induced pluripotent stem cells (iPSC); Mesenchymal stem cells (MSC); Reprogrammed induced pluripotent stem cells (iPSC) Cytokine identification; Differentiation of stem cells; Growth factor identification; Protein identification; Protein quantification; RNA gene expression Bicinchoninic acid (BCA) protein assay; Cytokine array; Differentiation staining and quantification; Exosome extraction; Flow cytometric characterisation; PCR - Conventional; Trilineage differentiation in-house methods

The only data displayed is that deemed relevant and necessary for the clear description of the Activities and Services covered by the Scope of Accreditation (SoA).

Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.

The Product column may also describe an Item or Material.

The Limitations column may also describe the Range.